Moreover, therapeutic strategies targeting noncoding RNAs (such as miR-21, miR-145-5P, and miR-145-29b) have shown efficacy in mitigating nephritis and fibrosis in chronic kidney disease models, primarily through inhibition of the TGF-β1/Smad pathway (87). The gene discussed is TGFB1; the disease is chronic kidney disease.